Piper Sandler analyst Adam Maeder lowered the firm’s price target on Inari Medical to $85 from $90 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that beat consensus estimates on the top and bottom-line driven by all-around strength. Additionally, Inari raised its full-year revenue guidance by $4.5M to $490-493M and Piper thinks the guidance could prove conservative again. Perhaps the biggest surprise this evening was the company’s acquisition of privately-held LimFlow Medical, which makes a device to treat CLTI.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NARI:
- Inari Medical to Present at Upcoming Investor Conferences
- Inari Medical Inari raises FY23 revenue view to $490M-$493M, consensus $487.9M
- Inari Medical to acquire privately held LimFlow for $250M in cash
- Inari Medical to acquire LimFlow in up to $415M deal
- Inari Medical reports Q3 EPS 5c, consensus 0c